219 related articles for article (PubMed ID: 20129244)
1. IDH1 mutations in gliomas: when an enzyme loses its grip.
Frezza C; Tennant DA; Gottlieb E
Cancer Cell; 2010 Jan; 17(1):7-9. PubMed ID: 20129244
[TBL] [Abstract][Full Text] [Related]
2. Glioma-derived mutations in IDH: from mechanism to potential therapy.
Fu Y; Huang R; Du J; Yang R; An N; Liang A
Biochem Biophys Res Commun; 2010 Jun; 397(2):127-30. PubMed ID: 20510884
[TBL] [Abstract][Full Text] [Related]
3. IDH mutations in glioma and acute myeloid leukemia.
Dang L; Jin S; Su SM
Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
[TBL] [Abstract][Full Text] [Related]
4. Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients.
Zhu J; Zuo J; Xu Q; Wang X; Wang Z; Zhou D
Med Hypotheses; 2011 Apr; 76(4):602-3. PubMed ID: 21284999
[TBL] [Abstract][Full Text] [Related]
5. Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas.
Weller M; Wick W; von Deimling A
Glia; 2011 Aug; 59(8):1200-4. PubMed ID: 21294161
[TBL] [Abstract][Full Text] [Related]
6. [IDH mutation on glioma].
Mukasa A
Gan To Kagaku Ryoho; 2011 Jun; 38(6):937-40. PubMed ID: 21751529
[No Abstract] [Full Text] [Related]
7. IDH1 and IDH2 mutations in gliomas.
Ducray F; Marie Y; Sanson M
N Engl J Med; 2009 May; 360(21):2248-9; author reply 2249. PubMed ID: 19469031
[No Abstract] [Full Text] [Related]
8. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A
Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
[TBL] [Abstract][Full Text] [Related]
9. Role of isocitrate dehydrogenase in glioma.
Alexander BM; Mehta MP
Expert Rev Neurother; 2011 Oct; 11(10):1399-409. PubMed ID: 21955197
[TBL] [Abstract][Full Text] [Related]
10. Glioma-derived mutations in isocitrate dehydrogenase 2 beneficial to traditional chemotherapy.
Fu Y; Huang R; Zheng Y; Zhang Z; Liang A
Biochem Biophys Res Commun; 2011 Jul; 410(2):218-23. PubMed ID: 21641335
[TBL] [Abstract][Full Text] [Related]
11. Metabolic syndromes and malignant transformation: where the twain shall meet.
Bhagwat N; Levine RL
Sci Transl Med; 2010 Oct; 2(54):54ps50. PubMed ID: 20962328
[TBL] [Abstract][Full Text] [Related]
12. Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1α and β-catenin signaling: possible impact on glioma cell metastasis and chemo-resistance.
Fu Y; Zheng S; Zheng Y; Huang R; An N; Liang A; Hu C
Int J Biochem Cell Biol; 2012 May; 44(5):770-5. PubMed ID: 22309944
[TBL] [Abstract][Full Text] [Related]
13. Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis.
Ohba S; Hirose Y
Neurol Med Chir (Tokyo); 2016; 56(4):170-9. PubMed ID: 26960449
[TBL] [Abstract][Full Text] [Related]
14. IDH1 mutations in gliomas: first series from a tertiary care centre in India with comprehensive review of literature.
Jha P; Suri V; Sharma V; Singh G; Sharma MC; Pathak P; Chosdol K; Jha P; Suri A; Mahapatra AK; Kale SS; Sarkar C
Exp Mol Pathol; 2011 Aug; 91(1):385-93. PubMed ID: 21569770
[TBL] [Abstract][Full Text] [Related]
15. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.
Kohanbash G; Carrera DA; Shrivastav S; Ahn BJ; Jahan N; Mazor T; Chheda ZS; Downey KM; Watchmaker PB; Beppler C; Warta R; Amankulor NA; Herold-Mende C; Costello JF; Okada H
J Clin Invest; 2017 Apr; 127(4):1425-1437. PubMed ID: 28319047
[TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance metabolic imaging of glioma.
Metellus P; Figarella-Branger D
Sci Transl Med; 2012 Jan; 4(116):116ps1. PubMed ID: 22238331
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the IDH1 codon 132 mutation in brain tumors.
Balss J; Meyer J; Mueller W; Korshunov A; Hartmann C; von Deimling A
Acta Neuropathol; 2008 Dec; 116(6):597-602. PubMed ID: 18985363
[TBL] [Abstract][Full Text] [Related]
18. IDH1 and IDH2 mutations in gliomas.
Cohen AL; Holmen SL; Colman H
Curr Neurol Neurosci Rep; 2013 May; 13(5):345. PubMed ID: 23532369
[TBL] [Abstract][Full Text] [Related]
19. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes.
Capper D; Sahm F; Hartmann C; Meyermann R; von Deimling A; Schittenhelm J
Am J Surg Pathol; 2010 Aug; 34(8):1199-204. PubMed ID: 20661018
[TBL] [Abstract][Full Text] [Related]
20. [Feature analysis of IDH1 mutation in oligodendroglial tumors].
Ren XH; Cui XL; Shang ZM; Lin S
Zhonghua Yi Xue Za Zhi; 2012 Mar; 92(11):724-6. PubMed ID: 22781348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
